Related Experiment Videos
Sequential combination chemotherapy in advanced breast cancer.
Cancer Chemotherapy and Pharmacology
|January 1, 1978
Summary
Sequential chemotherapy with Adriamycin plus Vincristine (AV) and Cyclophosphamide, Methotrexate, Fluorouracil (CMF) showed similar response rates and duration for advanced breast cancer. This combination therapy was not more toxic than single regimens.
Area of Science:
- Medical Oncology
- Clinical Pharmacology
Background:
- Advanced breast cancer treatment often involves combination chemotherapy.
- Non-cross resistant regimens are explored to improve treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy and toxicity of sequential alternating chemotherapy combinations in advanced breast cancer.
- To determine if sequential Adriamycin plus Vincristine (AV) followed by Cyclophosphamide, Methotrexate, Fluorouracil (CMF) improves response rates and duration compared to single combinations.
Main Methods:
- Prospective controlled study with 110 evaluable, chemotherapy-naive patients with advanced breast cancer.
- Random allocation to two treatment arms: Therapy A (2 AV then 2 CMF) and Therapy B (2 CMF then 2 AV).
Main Results:
- Overall response rates (complete plus partial) were similar between groups (53% vs 60%).
- Duration of remission was comparable (11 vs 12 months).
- Sequential combination therapy demonstrated similar toxicity profiles compared to single regimens.
Conclusions:
- Sequential alternating chemotherapy with AV and CMF is an effective treatment strategy for advanced breast cancer.
- This approach offers comparable efficacy and toxicity to single-agent combinations, suggesting potential for improved patient management.